We compared the ability of inhaled nitric oxide (NO), oxygen (O 2 ) and nitric oxide in oxygen (NOϩO 2 ) to identify reactive pulmonary vasculature in pulmonary hypertensive patients during acute vasodilator testing at cardiac catheterization.
CONCLUSIONS Inhaled NO and O 2 produced a similar degree of selective pulmonary vasodilation. Our data suggest that combination testing with NOϩO 2 provides additional pulmonary vasodilation in patients with a reactive pulmonary vascular bed in a selective, safe and expeditious fashion during cardiac catheterization. The combination of NOϩO 2 identifies patients with significant pulmonary vasoreactivity who might not be recognized if O 2 or NO were used separately. (J Am Coll Cardiol 1999;33:813-9) © 1999 by the American College of Cardiology Elevated pulmonary vascular resistance (PVR) complicates the evaluation, clinical course and outcome of patients with congenital heart disease or end-stage pulmonary disease. It is a crucial factor in determining the timing or type of intervention, and has been invoked as the primary determinant of mortality in many lesions (1, 2) . Opinion varies on what resistance must be achieved with vasodilator testing to insure safe operability for children with congenital heart disease. An increased or fixed elevation in PVR may deny patients the chance of corrective surgery, leaving them susceptible to the development of progressive obliterative pulmonary vascular disease and reduced life expectancy (3, 4) . Demonstration of pulmonary vasoreactivity in patients with end-stage pulmonary disease may differentiate patients who would benefit from long-term medical therapy (5, 6 ) from those with high, fixed resistance who should be more urgently considered for lung transplantation (3) . Safe and expeditious demonstration of maximal pulmonary vasodilation in patients with a reactive pulmonary bed is therefore an important objective. Many vasodilators have been utilized for diagnostic testing during cardiac catheterization. Systemic vasodilators with their attendant risks of hypotension and increased intrapulmonary shunt may be hazardous (7) , especially in patients with ventricular outflow tract obstruction. Breathing oxygen (O 2 ) remains a standard means of pulmonary vasodilator testing in pediatric cardiac catheterization laboratories (8, 9) . However, failure to respond to acute treatment with O 2 has been reported in some patients who did indeed have reactive pulmonary vasculature (3, 10) .
Inhaled nitric oxide (NO) is a selective pulmonary vasodilator with minimal systemic effects and does not increase intrapulmonary shunting. It can be administered easily with O 2 or room air (RA) during cardiac catheterization by either ventilator or mask. The purpose of this study was to compare the ability of NO and O 2 to identify patients with a reactive pulmonary vascular bed during cardiac catheter-ization. We further compared the hemodynamic effects of breathing nitric oxide in oxygen (NOϩO 2 ) to breathing O 2 alone during acute vasodilator testing.
METHODS
We enrolled patients between January 1992 and December 1996 who had mean pulmonary artery pressure Ն30 mm Hg, PVR Ͼ3 U⅐m 2 , and were determined during catheterization to require vasodilator testing. We included for analysis 71 patients who had complete hemodynamic measurements to allow calculation of vascular resistances.
Study groups. The first 46 patients (group 1) were studied under the following four study conditions: A) in RA; B) after breathing 100% O 2 for 15 min; C) after another 15 min in RA, and D) after 15 min breathing NO at 80 parts per million (ppm) in 23% O 2 (NOϩRA). As NO is titrated into a delivery circuit, the delivered fraction of inspired O 2 (FiO 2 ) is decreased. Therefore a small amount of supplemental O 2 (23%) was added to NO to avoid administration of a hypoxic gas mixture. The patients in group 1 had a median age of 6.5 years, range 4 months to 59 years.
Twenty-five additional patients (group 2) were studied in the following three conditions: A) in RA; B) after breathing 100% O 2 for 15 min, and C) after 15 min of inhaling 80 ppm NO in 91% O 2 . This was the maximal FiO 2 attainable after dilution with 80 ppm of NO. Patients in group 2 had a median age of 3.5 years, range 5 months to 69 years.
The patients in each group represented a broad spectrum of diagnoses characteristic of a high volume pediatric cardiac catheterization laboratory. Most had unrepaired or previously palliated congenital heart disease, although some had end-stage pulmonary disease (Tables 1 and 2) . Four of 46 patients in group 1 and three of 25 patients in group 2 were mechanically ventilated. The remainder in each group were breathing spontaneously. Sedation was given according to a routine, which included intravenous morphine and midazolam. Partial pressure of carbon dioxide (PCO 2 ) was normal throughout the study in both groups.
Hemodynamic assessment. Hemodynamic measurements included left atrial, right atrial, pulmonary and systemic arterial pressures during each of the conditions described above. Cardiac output was measured by thermodilution in patients without an intracardiac shunt. In those with shunts, O 2 consumption was measured (Waters Inc., model MM20, Rochester, Minnesota), and systemic and pulmonary blood flows were calculated using the Fick equation with inclusion of dissolved O 2 . Errors related to sampling site variances were minimized by ensuring that, for each patient, venous samples were collected at the same site during each of the study conditions. Delivery and monitoring of NO. Detailed descriptions of the technical aspects of our delivery of NO in both ventilated and spontaneously breathing patients have been published previously (11, 12) . We used NO gas (Scott Specialty Gases, Plumsteadville, Pennsylvania or BOC Gases, Murray Hill, New Jersey) of medical grade quality, which In parentheses is the number of patients who did not respond to either oxygen or nitric oxide. ASD ϭ atrial septal defect; ASO ϭ arterial switch operation; CAVC ϭ complete atrioventricular canal; PAB ϭ pulmonary artery band; PDA ϭ patent ductus arteriosus; Shone's syndrome ϭ multiple left-sided obstructive lesions; TAPVC ϭ total anomalous pulmonary venous connection; TGA ϭ transposition of the great arteries; TOF/PA ϭ tetralogy of Fallot with pulmonary atresia; VSD ϭ ventricular septal defect. conformed to Food and Drug Administration standards. In the spontaneously breathing individuals NO was delivered using the titration technique from source tanks with an 800-ppm concentration. Flow rates greater than the patients' minute volumes were delivered through a one-way inspiratory valve to a face mask. The expired gases were scavenged using a reservoir bag and regulated wall suction.
Abbreviations and Acronyms
In the seven patients who were mechanically ventilated, ventilator settings were kept constant throughout the study. 
. Groups 1 and 2 were analyzed separately with patients in each group acting as their own controls. Repeated measures analysis of variance was used to look for differences in the measurements over the four study conditions in group 1 and the three conditions in group 2. If differences were found, then the Bonferroni multiple comparisons procedure was used to determine where differences existed. A p value Ͻ0.05 was considered significant. In parentheses is the number of patients who did not respond to either oxygen or nitric oxide in oxygen. COPD ϭ chronic obstructive pulmonary disease; PV ϭ pulmonary vein; other abbreviations as in Table 1 . Mean systemic blood pressure increased over the three study conditions, from 76.8 Ϯ 2.9 mm Hg in RA to 80.6 Ϯ 2.5 mm Hg in O 2 to 83.4 Ϯ 2.6 mm Hg in NOϩO 2 . Blood pressure was significantly higher in NOϩO 2 than in RA, but not statistically different from blood pressure in O 2 . Cardiac index, systemic vascular resistance, right atrial pressure, heart rate, pH and PCO 2 did not change. Arterial Importance of vasodilator testing. The precise stage when pulmonary vascular disease has progressed to a point where surgical repair of congenital heart lesions cannot be safely performed is unknown. Morphologic criteria (2) and pulmonary hemodynamics (13) are useful, but imprecise. Pulmonary vascular resistance calculated to be more than 6 to 8 U⅐m 2 has been shown to be associated with poor operative outcome regardless of lung histology (1, 4, 14) . In contrast, patients who respond to vasodilators with a PVR less than 6 to 8 U⅐m 2 do well postoperatively (13) . Demonstration of a reactive pulmonary bed in patients being evaluated for transplantation has enabled patients to be offered a single organ heart instead of heart-lung block with successful results (15) . Patients with elevated resistance but reactive pulmonary vasculature may need more intensive postoperative care and presumably would be excellent candidates for NO therapy in the postoperative period should pulmonary hypertension emerge. Response to acute vasodilator testing in patients with primary pulmonary hypertension is an important marker for survival (3) and may identify patients who would benefit from chronic medical therapy (5, 6) .
RESULTS
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Comparison with other studies. Prior research in children with pulmonary hypertension has shown that O 2 failed to unmask all reversible pulmonary vasoconstriction (3, 10) . Prostacyclin administration in patients with pulmonary hypertension breathing O 2 caused further pulmonary vasodilation. However, prostacyclin can cause systemic side effects including tachycardia and hypotension (16) . Previous studies of vasoreactivity in children during cardiac catheterization found variable responsiveness to NO that seemed to (18 -20) . Each prior study, however, has had insufficient power to establish a significant difference in PVR. Nitric oxide causes vasorelaxation through a cyclic guanosine monophosphate-mediated pathway. The mechanism of vasorelaxation caused by O 2 is not clearly known (21) . The fact that some patients responded to one agent with significant vasodilation but not the other, and that the majority of patients experienced increased vasodilation with combination therapy compared with O 2 alone, suggests that the mechanisms may not be identical.
Potential toxicities. The major recognized toxicities associated with inhaling NO are cytotoxic effects in the lung due to exposure to excess NO 2 and methemoglobinemia due to the intravascular binding to hemoglobin. Nitrogen dioxide will develop in delivery systems at a rate that is proportional to NO and O 2 concentrations and contact times between the two gases. When NO was delivered with maximal amounts of O 2 in this study, NO 2 levels averaged 2.3 Ϯ 0.3 ppm, below the accepted environmental exposure level of 5 ppm (22) . Nitrogen dioxide should be continuously monitored, especially in patients mechanically ventilated with circuits that do not use continuous gas flows. If patients receive prolonged treatment with NO in high concentrations of O 2 , we recommend reduction in the NO dose to diminish potential dose-related toxicity. There have been no reports of clinically significant methemoglobinemia during brief exposure to NO at doses as high as 80 ppm. Methemoglobin measured at the conclusion of the 15-min period of NO inhalation in 22/46 patients was 0.8 Ϯ 0.1%. This along with previously published results (11) supports the contention that routine measurement of methemoglobin may be unnecessary during brief diagnostic trials of NO.
It is notable that the combination of NO in O 2 resulted in an increase in left atrial pressure compared with RA or O 2 alone. Reports have suggested that O 2 (23) or NO (24) may have deleterious effects to patients with heart failure. In this study no patient demonstrated clinically important pulmonary edema, hemodynamically significant systemic vasoconstriction or decreased cardiac index during the brief administration of O 2 or NO in O 2 . Nevertheless, we believe that NO, especially when used with O 2 , should be carefully monitored in patients with elevated left atrial pressures due to the potential induction of pulmonary edema.
Study limitations. The patient population studied was quite heterogeneous. However, this accurately reflects the typical spectrum of patients presenting for vasodilator testing during cardiac catheterization. Subgroup analysis of patients with congenital heart disease showed no differences in response compared to the group as a whole. Patients with lung pathology analyzed separately showed similar results, but numbers were too small to form conclusions. Subgroup analysis of patients with left to right shunts did not reveal any difference in response compared to those without shunts. The definition of responder and nonresponder is arbitrary, but a 20% change is often used in drug testing as a marker of responsiveness. There was no apparent predictive marker in patients who responded to one agent but not the other. It may be that repeated exposure to O 2 or NO would minimize differences between responders and nonresponders. Nonetheless, a single exposure to a drug is the common catheterization protocol. Limited information exists concerning optimal dosing of NO, with some investigators showing maximal vasodilation at doses as low as 2 ppm (19) , and others demonstrating a dose-response relationship up to 80 ppm in a similar population (18) . This study was designed as a brief diagnostic trial in a catheterization laboratory to determine the most effective and inclusive method of identifying patients with pulmonary vasoreactivity. Accordingly, 80 ppm was used during this brief testing with the appreciation that, if delivered for prolonged periods, it may be associated with dose-related increased toxicity. This study was not designed to demonstrate differences in long-term patient outcomes or clinical value of vasodilator testing. Maximal vasodilatory capacity may be of limited clinical value in some patients. Nevertheless, as a result of information acquired during combination therapy, some patients were offered surgery who did not respond to NO or O 2 alone; all patients survived.
Summary. Individually, NO and O 2 produced significant and comparable selective pulmonary vasodilation in a heterogeneous group of patients presenting to cardiac catheterization for pulmonary vasodilator testing. However, neither agent used separately identified all patients with the capacity to relax their pulmonary vascular bed. The combination of NOϩO 2 caused significantly greater pulmonary vasodilation compared to O 2 and identified patients who had pulmonary vasoreactivity that was not appreciated during O 2 breathing alone. This study suggests that combination testing with NOϩO 2 provides additional pulmonary vasodilation in patients with a reactive pulmonary vascular bed in a specific, safe and expeditious fashion during cardiac catheterization. Nitric oxide in O 2 distinguishes patients with significant pulmonary vasoreactivity who might not be identified using either agent separately.
